Answers are grounded in this paper and cite their sources.
Elderly TKA patients commonly suffer osteoporosis-related postoperative bone loss. High-quality 2-year RCT data on perioperative denosumab remains limited. To evaluate the 2-year effects of adjunct denosumab on systemic bone density expressed as DXA-derived T-scores, bone turnover biomarkers and postoperative functional outcomes in older adults with osteopenia or osteoporosis undergoing primary TKA. This single-center, prospective, open-label randomized controlled trial enrolled patients aged ≥ 60 years undergoing primary TKA between March 2024 and September 2024. The primary endpoints were changes in lumbar spine and femoral neck T-scores from baseline to 24 months, tested using a fixed-sequence procedure. Secondary outcomes included bone turnover markers, parathyroid hormone (PTH), 25-hydroxyvitamin D, serum calcium and phosphorus, Knee Society Scores (KSS), knee range of motion (ROM), and adverse events. The primary analysis included participants who received the allocated intervention and had post-baseline data. Of 104 randomized participants, 94 received the allocated intervention and completed 24-month follow-up; 10 withdrew before treatment initiation and had no post-baseline data. Compared with controls, participants receiving denosumab had higher lumbar spine T-scores at 12 months ( P = 0.034) and 24 months ( P = 0.014), as well as a higher femoral neck T-score at 24 months ( P = 0.048). From baseline to 24 months, between-group differences in T-score change favored denosumab for the lumbar spine (0.37, 95% CI 0.13–0.61; P = 0.003) and femoral neck (0.27, 95% CI 0.01–0.53; P = 0.040). Denosumab was associated with lower β-CTX concentrations at 6, 12, and 24 months and lower PTH concentrations at 12 and 24 months ( P < 0.05). Exploratory analyses showed greater lumbar spine T-score benefits in participants with osteoporosis, age ≥ 70 years, or KL grade 4 osteoarthritis. KSS clinical and function scores and knee ROM were also higher in the denosumab group at selected follow-up points, although these functional findings were exploratory. Adverse-event rates were similar between groups, and no severe adverse events were observed during follow-up. In this randomized trial of older adults with low bone mass undergoing primary TKA, adjunctive denosumab was associated with more favorable lumbar spine and femoral neck T-score changes and sustained suppression of bone resorption over 24 months. Functional differences were exploratory, and the clinical significance of the observed skeletal and functional effects requires confirmation in larger, blinded trials with longer follow-up.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: